Clinical Trial Results:
A Randomised Phase III Trial comparing 16 to 18 weeks of neoadjuvant Exemestane (25mg daily), Letrozole (2.5mg), or Anastrozole(1mg) in postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Summary
|
|
EudraCT number |
2006-000513-37 |
Trial protocol |
IE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
22 Sep 2023
|
First version publication date |
22 Sep 2023
|
Other versions |
|
Summary report(s) |
2006-000513-37_Results_redacted |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.